CIT v Eli Lilly and Co

Facts

• Eli Lilly India incurred substantial expenditure on VRS payments to employees
• The VRS was part of a restructuring exercise
• The assessee claimed the entire VRS expenditure as deductible revenue expenditure under S.37(1)
• The AO/CIT disallowed the claim, treating it as capital expenditure (enduring benefit of permanent workforce reduction)
• The matter reached the Supreme Court

Issues

1. Whether VRS payments to employees constitute revenue or capital expenditure
2. Whether the "enduring benefit" test makes VRS payments capital in nature

Held

• VRS payments are revenue expenditure deductible under S.37(1)
• They discharge an obligation to employees; they do not create any new asset or enduring advantage
• The reduction in workforce is a consequence, not an asset; it does not have a money value that can be identified as capital
• The expenditure is wholly and exclusively for the purpose of business
• Deduction allowed in the year of payment

Ratio Decidendi

The character of expenditure (revenue vs capital) is determined by what it achieves, not what it causes. VRS payment achieves release of employees from service; it does not acquire or create an asset. The enduring benefit test applies to tangible or identifiable advantages of a capital nature. A leaner workforce is an operational consequence, not an identifiable capital asset.